Logo image of DTIL

PRECISION BIOSCIENCES INC (DTIL) Stock Fundamental Analysis

NASDAQ:DTIL - Nasdaq - US74019P2074 - Common Stock - Currency: USD

4.25  -0.05 (-1.16%)

Fundamental Rating

2

Overall DTIL gets a fundamental rating of 2 out of 10. We evaluated DTIL against 555 industry peers in the Biotechnology industry. Both the profitability and financial health of DTIL have multiple concerns. While showing a medium growth rate, DTIL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DTIL had negative earnings in the past year.
In the past year DTIL has reported a negative cash flow from operations.
In the past 5 years DTIL reported 4 times negative net income.
DTIL had a negative operating cash flow in each of the past 5 years.
DTIL Yearly Net Income VS EBIT VS OCF VS FCFDTIL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

The Return On Assets of DTIL (-17.67%) is better than 79.10% of its industry peers.
The Return On Equity of DTIL (-44.56%) is better than 67.75% of its industry peers.
Industry RankSector Rank
ROA -17.67%
ROE -44.56%
ROIC N/A
ROA(3y)-26.66%
ROA(5y)-33.41%
ROE(3y)-165.71%
ROE(5y)-155.21%
ROIC(3y)N/A
ROIC(5y)N/A
DTIL Yearly ROA, ROE, ROICDTIL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DTIL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DTIL Yearly Profit, Operating, Gross MarginsDTIL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

DTIL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DTIL has been increased compared to 1 year ago.
Compared to 5 years ago, DTIL has more shares outstanding
The debt/assets ratio for DTIL is higher compared to a year ago.
DTIL Yearly Shares OutstandingDTIL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
DTIL Yearly Total Debt VS Total AssetsDTIL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

DTIL has an Altman-Z score of -5.37. This is a bad value and indicates that DTIL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of DTIL (-5.37) is worse than 62.16% of its industry peers.
A Debt/Equity ratio of 0.45 indicates that DTIL is not too dependend on debt financing.
The Debt to Equity ratio of DTIL (0.45) is worse than 73.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Altman-Z -5.37
ROIC/WACCN/A
WACC8.04%
DTIL Yearly LT Debt VS Equity VS FCFDTIL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

DTIL has a Current Ratio of 6.62. This indicates that DTIL is financially healthy and has no problem in meeting its short term obligations.
DTIL has a better Current ratio (6.62) than 64.50% of its industry peers.
DTIL has a Quick Ratio of 6.62. This indicates that DTIL is financially healthy and has no problem in meeting its short term obligations.
DTIL's Quick ratio of 6.62 is fine compared to the rest of the industry. DTIL outperforms 64.68% of its industry peers.
Industry RankSector Rank
Current Ratio 6.62
Quick Ratio 6.62
DTIL Yearly Current Assets VS Current LiabilitesDTIL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.86% over the past year.
DTIL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -11.11%.
DTIL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.30% yearly.
EPS 1Y (TTM)78.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-531.43%
Revenue 1Y (TTM)-11.11%
Revenue growth 3Y-15.91%
Revenue growth 5Y25.3%
Sales Q2Q%-99.84%

3.2 Future

The Earnings Per Share is expected to grow by 59.21% on average over the next years. This is a very strong growth
Based on estimates for the next years, DTIL will show a decrease in Revenue. The Revenue will decrease by -4.96% on average per year.
EPS Next Y-4029.86%
EPS Next 2Y-368.66%
EPS Next 3Y-163.48%
EPS Next 5Y59.21%
Revenue Next Year-69.62%
Revenue Next 2Y-37.11%
Revenue Next 3Y-24.32%
Revenue Next 5Y-4.96%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
DTIL Yearly Revenue VS EstimatesDTIL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
DTIL Yearly EPS VS EstimatesDTIL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DTIL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DTIL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DTIL Price Earnings VS Forward Price EarningsDTIL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DTIL Per share dataDTIL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A cheap valuation may be justified as DTIL's earnings are expected to decrease with -163.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-368.66%
EPS Next 3Y-163.48%

More info and screens

0

5. Dividend

5.1 Amount

DTIL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRECISION BIOSCIENCES INC

NASDAQ:DTIL (6/30/2025, 12:47:11 PM)

4.25

-0.05 (-1.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners43.39%
Inst Owner Change-1.82%
Ins Owners8.62%
Ins Owner Change0.96%
Market Cap47.13M
Analysts84
Price Target21.93 (416%)
Short Float %5.85%
Short Ratio4.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.53%
Min EPS beat(2)-26.21%
Max EPS beat(2)-10.86%
EPS beat(4)1
Avg EPS beat(4)88.1%
Min EPS beat(4)-26.21%
Max EPS beat(4)404.22%
EPS beat(8)4
Avg EPS beat(8)57.21%
EPS beat(12)6
Avg EPS beat(12)37%
EPS beat(16)9
Avg EPS beat(16)43.8%
Revenue beat(2)0
Avg Revenue beat(2)-92.4%
Min Revenue beat(2)-99.43%
Max Revenue beat(2)-85.37%
Revenue beat(4)1
Avg Revenue beat(4)44.12%
Min Revenue beat(4)-99.43%
Max Revenue beat(4)452.4%
Revenue beat(8)4
Avg Revenue beat(8)70.6%
Revenue beat(12)7
Avg Revenue beat(12)55.44%
Revenue beat(16)9
Avg Revenue beat(16)79.12%
PT rev (1m)0%
PT rev (3m)-36.01%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2133.33%
EPS NY rev (1m)4.81%
EPS NY rev (3m)-12.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-54.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)9.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.92
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-2.01
EYN/A
EPS(NY)-3.29
Fwd EYN/A
FCF(TTM)-5.32
FCFYN/A
OCF(TTM)-5.28
OCFYN/A
SpS4.61
BVpS4.45
TBVpS4.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.67%
ROE -44.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.66%
ROA(5y)-33.41%
ROE(3y)-165.71%
ROE(5y)-155.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.94%
Cap/Sales 0.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.62
Quick Ratio 6.62
Altman-Z -5.37
F-Score3
WACC8.04%
ROIC/WACCN/A
Cap/Depr(3y)28.02%
Cap/Depr(5y)41.2%
Cap/Sales(3y)6.1%
Cap/Sales(5y)8.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-531.43%
EPS Next Y-4029.86%
EPS Next 2Y-368.66%
EPS Next 3Y-163.48%
EPS Next 5Y59.21%
Revenue 1Y (TTM)-11.11%
Revenue growth 3Y-15.91%
Revenue growth 5Y25.3%
Sales Q2Q%-99.84%
Revenue Next Year-69.62%
Revenue Next 2Y-37.11%
Revenue Next 3Y-24.32%
Revenue Next 5Y-4.96%
EBIT growth 1Y-27.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-100.82%
EBIT Next 3Y-6.79%
EBIT Next 5Y-11.5%
FCF growth 1Y-14.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.04%
OCF growth 3YN/A
OCF growth 5YN/A